Literature DB >> 33651408

hnRNP L is essential for myogenic differentiation and modulates myotonic dystrophy pathologies.

Matthew S Alexander1,2,3,4, Rylie M Hightower1,2, Andrea L Reid1, Alexis H Bennett5, Lakshmanan Iyer6, Donna K Slonim7, Madhurima Saha8, Genri Kawahara9, Louis M Kunkel10,11,12,13, Alan S Kopin14, Vandana A Gupta5, Peter B Kang8,15,16,17,18,19, Isabelle Draper14.   

Abstract

INTRODUCTION: RNA-binding proteins (RBPs) play an important role in skeletal muscle development and disease by regulating RNA splicing. In myotonic dystrophy type 1 (DM1), the RBP MBNL1 (muscleblind-like) is sequestered by toxic CUG repeats, leading to missplicing of MBNL1 targets. Mounting evidence from the literature has implicated other factors in the pathogenesis of DM1. Herein we sought to evaluate the functional role of the splicing factor hnRNP L in normal and DM1 muscle cells.
METHODS: Co-immunoprecipitation assays using hnRNPL and MBNL1 expression constructs and splicing profiling in normal and DM1 muscle cell lines were performed. Zebrafish morpholinos targeting hnrpl and hnrnpl2 were injected into one-cell zebrafish for developmental and muscle analysis. In human myoblasts downregulation of hnRNP L was achieved with shRNAi. Ascochlorin administration to DM1 myoblasts was performed and expression of the CUG repeats, DM1 splicing biomarkers, and hnRNP L expression levels were evaluated.
RESULTS: Using DM1 patient myoblast cell lines we observed the formation of abnormal hnRNP L nuclear foci within and outside the expanded CUG repeats, suggesting a role for this factor in DM1 pathology. We showed that the antiviral and antitumorigenic isoprenoid compound ascochlorin increased MBNL1 and hnRNP L expression levels. Drug treatment of DM1 muscle cells with ascochlorin partially rescued missplicing of established early biomarkers of DM1 and improved the defective myotube formation displayed by DM1 muscle cells. DISCUSSION: Together, these studies revealed that hnRNP L can modulate DM1 pathologies and is a potential therapeutic target.
© 2021 Wiley Periodicals LLC.

Entities:  

Keywords:  MBNL; ascochlorin; hnRNP L; myotonic dystrophy; smooth

Mesh:

Substances:

Year:  2021        PMID: 33651408      PMCID: PMC8131270          DOI: 10.1002/mus.27216

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.852


  65 in total

Review 1.  Gene regulatory networks and transcriptional mechanisms that control myogenesis.

Authors:  Margaret Buckingham; Peter W J Rigby
Journal:  Dev Cell       Date:  2014-02-10       Impact factor: 12.270

2.  Mice transgenic for the human myotonic dystrophy region with expanded CTG repeats display muscular and brain abnormalities.

Authors:  H Seznec; O Agbulut; N Sergeant; C Savouret; A Ghestem; N Tabti; J C Willer; L Ourth; C Duros; E Brisson; C Fouquet; G Butler-Browne; A Delacourte; C Junien; G Gourdon
Journal:  Hum Mol Genet       Date:  2001-11-01       Impact factor: 6.150

Review 3.  Myotonic dystrophy: is a narrow focus obscuring the rest of the field?

Authors:  Mani S Mahadevan
Journal:  Curr Opin Neurol       Date:  2012-10       Impact factor: 5.710

4.  Aberrant splicing and expression of the non muscle myosin heavy-chain gene MYH14 in DM1 muscle tissues.

Authors:  F Rinaldi; C Terracciano; V Pisani; R Massa; E Loro; L Vergani; S Di Girolamo; C Angelini; G Gourdon; G Novelli; A Botta
Journal:  Neurobiol Dis       Date:  2011-08-18       Impact factor: 5.996

5.  Three proteins, MBNL, MBLL and MBXL, co-localize in vivo with nuclear foci of expanded-repeat transcripts in DM1 and DM2 cells.

Authors:  Majid Fardaei; Mark T Rogers; Helena M Thorpe; Kenneth Larkin; Marion G Hamshere; Peter S Harper; J David Brook
Journal:  Hum Mol Genet       Date:  2002-04-01       Impact factor: 6.150

6.  Systemic therapy in an RNA toxicity mouse model with an antisense oligonucleotide therapy targeting a non-CUG sequence within the DMPK 3'UTR RNA.

Authors:  Ramesh S Yadava; Qing Yu; Mahua Mandal; Frank Rigo; C Frank Bennett; Mani S Mahadevan
Journal:  Hum Mol Genet       Date:  2020-06-03       Impact factor: 6.150

Review 7.  Pathogenic mechanisms of myotonic dystrophy.

Authors:  Johanna E Lee; Thomas A Cooper
Journal:  Biochem Soc Trans       Date:  2009-12       Impact factor: 5.407

8.  Reversal of RNA dominance by displacement of protein sequestered on triplet repeat RNA.

Authors:  Thurman M Wheeler; Krzysztof Sobczak; John D Lueck; Robert J Osborne; Xiaoyan Lin; Robert T Dirksen; Charles A Thornton
Journal:  Science       Date:  2009-07-17       Impact factor: 47.728

9.  Smaug/SAMD4A restores translational activity of CUGBP1 and suppresses CUG-induced myopathy.

Authors:  Maria de Haro; Ismael Al-Ramahi; Karlie R Jones; Jerrah K Holth; Lubov T Timchenko; Juan Botas
Journal:  PLoS Genet       Date:  2013-04-18       Impact factor: 5.917

10.  Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9.

Authors:  Yanlin Wang; Lei Hao; Hongcai Wang; Katherine Santostefano; Arjun Thapa; John Cleary; Hui Li; Xiuming Guo; Naohiro Terada; Tetsuo Ashizawa; Guangbin Xia
Journal:  Mol Ther       Date:  2018-09-11       Impact factor: 11.454

View more
  1 in total

1.  RNA-binding proteins modulate drug sensitivity of cancer cells.

Authors:  Oliver Rogoyski; André P Gerber
Journal:  Emerg Top Life Sci       Date:  2021-11-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.